We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
05 Sep 2020 - 09 Sep 2020
Virtual Venue

Pediatric CKD Progression Linked to Low Serum Bicarbonate

By LabMedica International staff writers
Posted on 02 Jul 2020
Print article
Image: Low levels of bicarbonate in the blood were linked to a higher risk of progression to chronic kidney disease (Photo courtesy of Blood Tests London).
Image: Low levels of bicarbonate in the blood were linked to a higher risk of progression to chronic kidney disease (Photo courtesy of Blood Tests London).
Metabolic acidosis is a serious electrolyte disorder characterized by an imbalance in the body's acid-base balance. Metabolic acidosis has three main root causes: increased acid production, loss of bicarbonate, and a reduced ability of the kidneys to excrete excess acids.

Chronic kidney disease (CKD) is a major health problem worldwide. Although relatively uncommon in children, it can be a devastating illness with many long-term consequences. CKD presents unique features in childhood and may be considered, at least in part, as a stand-alone nosologic entity.

Nephrologists at the Children’s National Hospital (Washington, DC, USA) and their colleagues carried out a prospective cohort study of pediatric patients aged 6 months to 16 years with mild to moderate CKD, 603 patients with non-glomerular disease and 255 patients with glomerular disease were included. Patients were analyzed for CKD progression of a 50% decline in baseline eGFR after exposure to serum bicarbonate. Analysis was stratified by glomerular diagnoses and adjusted for alkali therapy utilization.

The scientists reported that at baseline, 39% (237 of 603) of participants with non-glomerular disease had a bicarbonate level of ≤ 22 mEq/L and 36% (85 of 237) of those participants reported alkali therapy treatment. In participants with glomerular disease, 31% (79 of 255) had a bicarbonate of ≤ 22 mEq/L, 18% (14 of 79) of those participants reported alkali therapy treatment. Further adjusted longitudinal analyses compared non-glomerular disease patients with a bicarbonate level of greater than 22 mEq/L, hazard ratios associated with a bicarbonate level of less than 18 mEq/L were calculated at 1.28 and bicarbonate level of less than 19 mEq/L to 22 mEq/L at 0.91. In patients with glomerular disease, adjusted hazard ratios associated with bicarbonate level of at least 18 mEq/L were calculated as 2.16 and bicarbonate of at least 19 mEq/L to 22 mEq/L at 1.74.

Denver D. Brown, MD, a Pediatric Nephrologist and the lead author of the study, said, “Pediatric CKD exacts a large clinical and economic toll. Children with CKD have higher risk for hospitalizations, metabolic abnormalities, cardiovascular disease, growth restriction and cognitive impairment.”

The authors concluded that in children with glomerular disease, low bicarbonate was linked to a higher risk of CKD progression. Resolution of low bicarbonate was associated with a lower risk of CKD progression. Fewer than one half of all children with low bicarbonate reported treatment with alkali therapy. Long-term studies of alkali therapy’s effect in patients with pediatric CKD are needed. The study was published on June 8, 2020 in the Clinical Journal of the American Society of Nephrology.

Related Links:
Children’s National Hospital

Print article


Molecular Diagnostics

view channel
Image: Micrograph of gold nanostar biosensors used to detect cancer-related microRNAs (Photo courtesy of Duke University School of Engineering)

Nanostar Biosensors Use Raman Scattering for Direct Detection of Cancer-Related MicroRNAs

A novel non-invasive nanoparticle-based assay detects cancer-related microRNAs without use of labels or target amplification. MicroRNAs (miRNAs) comprise a class of about 20 nucleotides-long RNA fragments... Read more

Industry News

view channel
Image: ChemWell RPR Analyzer (Photo courtesy of Awareness Technology, Inc.)

Awareness Technology Announces ChemWell RPR Analyzer - The Most Significant Innovation in Syphilis Testing in Last 30 Years

Awareness Technology, Inc. (Palm City, FL, USA) has announced the most significant innovation in syphilis testing in the last 30 years with the launch of the ChemWell RPR automated nontreponemal analyzer... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.